與國(guó)際上ATCC、DSMZ、JCRB和RIKEN 公布的STR數(shù)據(jù)庫(kù)中8000余種細(xì)胞均不相符，排除被常見細(xì)胞系污染的可能。由于Hth-7細(xì)胞本身沒有公布可比對(duì)的STR圖譜數(shù)據(jù)，我們只能初步判斷該細(xì)胞可能為Hth-7。STR結(jié)果如下：D5S818: 11；D13S317: 11,14；D7S820: 8,11；D16S539: 9,13；vWA: 14,18；THO1: 9,9.3；Amelogenin: X；TPOX: 11；CSF1PO: 12經(jīng)無(wú)支原體鑒定入庫(kù)。

動(dòng)物種別：人

組織來(lái)源：甲狀腺

形態(tài)：貼壁生長(zhǎng)

培養(yǎng)基配方：

90%DMEM(MD0100)+10%胎牛血清(SD0200)+G/A (SD0038)

DMEM完全培養(yǎng)基（MD0101）

氣相：空氣，95%；二氧化碳，5%。 溫度：37℃。

凍存條件：基礎(chǔ)培養(yǎng)基+5%DMSO+20%FBS(SD0200)

完全凍存液：免程序降溫細(xì)胞凍存液（低血清）(SD0001)

聲明：產(chǎn)品僅科研使用。

PubMed=6220172

Dracopoli N.C., Fogh J.

Polymorphic enzyme analysis of cultured human tumor cell lines.

J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=17465858; DOI=10.1089/thy.2006.0246

Lee J.J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E., Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.

Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.

Thyroid 17:289-301(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102

Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690

Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

Clin. Cancer Res. 17:7248-7264(2011)

PubMed=23833040; DOI=10.1210/jc.2013-2383

Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25365311; DOI=10.1210/jc.2014-2359

Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.T., Chang W.J., Yang H., Ogawa S., Koeffler H.P.

Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.

J. Clin. Endocrinol. Metab. 100:725-735(2015)

PubMed=26680454; DOI=10.1186/s12885-015-1955-9

Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y., Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.

The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.

BMC Cancer 15:984-984(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953

Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Clin. Cancer Res. 25:3141-3151(2019)